

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 17, 2001, 16:55:27 ; Search time 37.5 seconds
(without alignments)

415.476 Million cell updates/sec

Title: US-09-403-724-5

Perfect score: 1415

Sequence: 1 CGLRLHRRQRIIGKNSL.....PGVYTKVSFAFVPIKSVTKL 257

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 412676 seqs, 60623988 residues

Total number of hits satisfying chosen parameters: 412676

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_0601.*

1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.*
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.*
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.*
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.*
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.*
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.*
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.*
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.*
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.*
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.*
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.*
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.*
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.*
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.*
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.*
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.*
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.*
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.*
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.*
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.*
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.*
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1415	100.0	822	20 AAW99087	Human serine prote
2	1415	100.0	875	20 AAW83361	Human neurotrypsin
3	1298	91.7	761	20 AAW99088	Mouse serine prote
4	1298	91.7	761	20 AAW83362	Mouse neurotrypsin
5	467	33.0	526	11 AAR09227	t-PA deletion vari
6	463.5	32.8	437	10 AAR94410	Sequence of coding
7	463.5	32.8	483	16 AAR70890	Human tissue PA va
8	463.5	32.8	527	11 AAR06236	Novel tissue plasm
9	463.5	32.8	527	11 AAR09278	t-PA variant H432A
10	463.5	32.8	527	16 AAR70868	Human t-PA variant
11	463.5	32.8	527	16 AAR70903	Human t-PA variant

12	463.5	32.8	562	11 AAR04700	Sequence of tissue
13	462.5	32.7	525	11 AAR09230	t-PA deletion vari
14	462.5	32.7	562	9 AAP82582	Tissue plasminogen
15	462	32.7	356	19 AAW46917	Amino acid sequenc
16	462	32.7	526	11 AAR09228	t-PA deletion vari
17	462	32.7	1042	21 AAR09228	Human serine prote
18	461	32.6	296	21 AAY72108	Human serine prote
19	461	32.6	372	21 AAY72092	t-PA insertion var
20	461	32.6	528	11 AAR09216	Mouse Serine prote
21	461	32.6	1113	21 AAY44427	t-PA deletion vari
22	460	32.5	526	11 AAR09229	t-PA deletion vari
23	459.5	32.5	525	11 AAR09238	t-PA deletion vari
24	459.5	32.5	527	11 AAR09281	Human t-PA variant
25	459.5	32.5	527	16 AAR70871	Human t-PA variant
26	459.5	32.5	527	16 AAR70906	T-PA variant havin
27	459.5	32.5	559	12 AAR13154	Sequence of full l
28	459.5	32.5	562	4 AAP30001	T-PA variant havin
29	459.5	32.5	562	12 AAR12423	MB1083 t-PA varian
30	459.5	32.5	562	12 AAR13442	t-PA deletion vari
31	459	32.4	526	11 AAR09225	t-PA deletion vari
32	459	32.4	526	11 AAR09226	Human tissue PA va
33	458.5	32.4	483	16 AAR70889	Human tissue PA va
34	458.5	32.4	483	16 AAR79144	Human tissue PA va
35	458.5	32.4	483	16 AAR70884	Human tissue PA va
36	458.5	32.4	483	16 AAR70885	Human tissue PA va
37	458.5	32.4	483	16 AAR70886	Human tissue PA va
38	458.5	32.4	483	16 AAR70887	Human tissue PA va
39	458.5	32.4	483	16 AAR70888	Human tissue PA va
40	458.5	32.4	483	16 AAR70850	Human tissue PA va
41	458.5	32.4	483	16 AAR70852	Human tissue PA va
42	458.5	32.4	483	16 AAR70851	Human tissue PA va
43	458.5	32.4	483	16 AAR70853	Human tissue PA va
44	458.5	32.4	483	16 AAR70854	Human tissue PA va
45	458.5	32.4	483	16 AAR70855	Human tissue PA va

ALIGNMENTS

RESULT 1
AAW99087
ID AAW99087 standard; Protein; 822 AA.
AC AAW99087;
XX
XX 13-MAY-1999 (first entry)
DT
XX Human serine protease BSSP-3.
DE
XX Serine protease; BSSP-3; brain tissue.
XX Homo sapiens.
XX
XX WO9905290-A1.
XX
XX 04-FEB-1999.
XX
XX 24-JUL-1998; 98WO-JF03324.
XX
XX 24-JUL-1997; 97JP-0213969.
XX
XX (SUNR) SUNTORY LTD.

XX
XX Tsuruoka N, Yamaguchi N, Yamashiro K;
PI
XX WPI: 1999-142942/12.
DR
XX N-PSDB; AAX19024.
DR
XX
XX New serine protease expressed in brain tissue - used in screening
PT for potential serine protease inhibitors for drug use
XX
XX Claim 1; Page 61-65; 69pp; Japanese.
XX

XX New serine protease expressed in brain tissue - used in screening
PT for potential serine protease inhibitors for drug use
XX
XX Example 1; Page 51-54; 69pp; Japanese.
XX
CC The present sequence is a serine protease designated BSSP-3, which
CC is isolated from mouse brain tissue. Transformants may be used to
CC produce the enzyme or its partial sequences. Products from the present
CC invention are used for screening for potential peptide or non-peptide
CC serine protease inhibitors or expression regulators for use as drugs.
XX
XX Sequence 761 AA;
XX

Query Match 91.7%; Score 1298; DB 20; Length 761;
Best Local Similarity 90.3%; Pred. No. 7.4e-108;
Matches 232; Conservative 12; Mismatches 13; Indels 0; Gaps 0;

QY 1 CGLRLHRRQKRIIGKNSLRGWPQVSLRLKSSHGDRLLCGATLLSSCWVLTAAHCF 60
DB 505 cglrlhrrqkriigknsrlrgawpqlrsahgdgrllcgatllsscwvltaaahcf 564

QY 61 KRYGNSTRSYAVRVGDYHTLVPEEFEEIGVQOIVIHREYRPRDSYDIALVRLQGPPEQ 120
DB 565 krygnnsrsvyavrvgydhtlvpeefeegvqgqivihnrprdsydyialvrlqgppeg 624

QY 121 CARFSSHVLPACLPWRERPKQTASNCYITGWGDTGRAYSRITLQQAIPLLPKRFCEERY 180
DB 625 carlsthvlpacplwrerpqktasnchitgwdtgraystrtlqqaavpllpkrfckery 684

QY 181 KGRFTGRMLCAGNLHEHKKRVDSGCGPLMCEPGEVWVYGVTSWGYCGVKDPSGV 240
DB 685 kgftgrmlcagnlhckrvdscgsgplmcepdeswvvygvtswgycgvkdpvgv 744

QY 241 YTKVSFAFVPWIKSVTKL 257
DB 745 ytrvpafvpwiksvtsl 761

RESULT 4
AAW83362 AAW83362 standard; Protein; 761 AA.
XX ID AAW83362
XX AC AAW83362;
XX DT 17-FEB-1999 (first entry)
XX DE Mouse neurotrypsin.
XX KW Mouse; neurotrypsin; tumour inhibition; neurological disease;
XX KW lung disease; gene therapy; drug development; stroke; brain injury;
XX KW neurodegeneration; neuroinflammatory disease; multiple sclerosis;
XX KW epilepsy; hypoxia; ischaemia; nerve transection; neuroangiogenesis;
XX KW emphysema; bronchitis.
XX OS Mus musculus.
XX PN W09849322-A1.
XX PD 05-NOV-1998.
XX PF 24-APR-1998; 98WO-IB00625.
XX PR 26-APR-1997; 97CH-0000966.
XX PA (SOND/) SONDEREGGER P.
XX PI Sonderegger P;
XX WPI: 1999-009438/01.
XX DR N-PSDB; AAV72590.
XX

PT New human and murine neurotrypsin - used, e.g. for inhibiting
PT tumours, treatment of neurological or lung disease, including by
PT gene therapy and in drug development
XX
XX Claim 1; Page 29-32; 50pp; English.
XX
CC The present sequence represents mouse neurotrypsin. Neurotrypsin proteins
CC and polynucleotides can be used: (i) to inhibit tumours, including
CC metastases, e.g. of brain or retina; (ii) to minimise tissue damage
CC caused by stroke or brain injury (having a protective effect on the
CC penumbra zone); (iii) to treat or prevent neurodegeneration,
CC neuroinflammatory disease (e.g. multiple sclerosis) or epilepsy; (iv) to
CC increase survival of damaged neurons (e.g. in cases of hypoxia,
CC ischaemia, nerve transection) and to stimulate regeneration and/or
CC restoration of synapses; (v) to treat or prevent retinal disorders (e.g.
CC degeneration or neovascularisation); (vi) to prevent apoptosis (or other
CC causes of cell death) in the nervous system; (vii) to regenerate brain
CC and/or nervous tissue; (viii) to treat pain; (ix) to improve brain
CC performance, including learning and memory; (x) to treat or prevent a
CC wide range of psychiatric disorders; and (xi) to treat brain or lung
CC injury associated with protease expression (specifically emphysema or
CC bronchitis).
XX
XX Sequence 761 AA;
XX

Query Match 91.7%; Score 1298; DB 20; Length 761;
Best Local Similarity 90.3%; Pred. No. 7.4e-108;
Matches 232; Conservative 12; Mismatches 13; Indels 0; Gaps 0;

QY 1 CGLRLHRRQKRIIGKNSLRGWPQVSLRLKSSHGDRLLCGATLLSSCWVLTAAHCF 60
DB 505 cglrlhrrqkriigknsrlrgawpqlrsahgdgrllcgatllsscwvltaaahcf 564

QY 61 KRYGNSTRSYAVRVGDYHTLVPEEFEEIGVQOIVIHREYRPRDSYDIALVRLQGPPEQ 120
DB 565 krygnnsrsvyavrvgydhtlvpeefeegvqgqivihnrprdsydyialvrlqgppeg 624

QY 121 CARFSSHVLPACLPWRERPKQTASNCYITGWGDTGRAYSRITLQQAIPLLPKRFCEERY 180
DB 625 carlsthvlpacplwrerpqktasnchitgwdtgraystrtlqqaavpllpkrfckery 684

QY 181 KGRFTGRMLCAGNLHEHKKRVDSGCGPLMCEPGEVWVYGVTSWGYCGVKDPSGV 240
DB 685 kgftgrmlcagnlhckrvdscgsgplmcepdeswvvygvtswgycgvkdpvgv 744

QY 241 YTKVSFAFVPWIKSVTKL 257
DB 745 ytrvpafvpwiksvtsl 761

RESULT 5
AAW83362 AAW83362 standard; Protein; 761 AA.
XX ID AAW83362
XX AC AAW83362;
XX DT 24-FEB-1993 (first entry)
XX DE t-PA deletion variant d303.
XX KW Tissue plasminogen activator; zymogen; clot; plasma; plasmin.
XX OS Homo sapiens.
XX PN Key Location/Qualifiers
XX FT Key 302..303
XX FT /label= deletion
XX FT /note= "the amino acid at position 303 of the
XX wild-type mature t-PA has been deleted"
XX W09002798-A.
XX

PD 31-JAN-1995.
XX
XX
XX 20-MAY-1988; 88US-0196909.
XX
PR 20-MAY-1988; 88US-0196909.
PR 15-FEB-1990; 90US-0480691.
PR 21-JAN-1992; 92US-0824740.
XX 22-MAR-1993; 93US-0035427.
XX
XX (GETH) GENENTECH INC.
XX
XX Anderson S, Brady KM, Keyt BA, Presta LG;
PI WPI; 1995-081536/11.
XX
XX New tissue plasminogen activator variants - having an N-linked
PT tripeptidyl glycosylation sequence inserted to increase plasma
PT half-life
XX
XX Claim 12; ; 34pp; English.
XX
XX The amino acid sequence of the human tissue plasminogen activator
CC (t-PA) variant N67,A432,A434.
CC This sequence varies from the wild type sequence (AAR70842) by
CC substitutions of AA at pos.: 67 - Y to N; 432 - H to A; 434 - R to A.
CC The numbers correspond to the residue positions in the wild type t-PA.
CC This sequence is one of a series of fibrinolytically active variant
CC t-PAs (see AAR70843-70908 + AAR79144). The variants are modified to
CC contain one or more amino acid substitutions, which provide an
CC Asn-X-Ser/Thr tripeptidyl sequence starting at the positions 57-61,
CC 63-69, 99, 101, 103-105, 106, 107, 109, 112, or 250 of the wild type t-PA
CC amino acid sequence. The Asn of the tripeptidyl sequence contains an
CC N-linked glycosylation site. The variant t-PAs exhibit fibrinolytic
CC activity and have longer half-lives and slower clearance rates from the
CC blood as compared to native t-PA. The variants can be used as
CC clot-dissolving agents in the treatment of vascular diseases or
CC conditions such as deep vein thrombosis or peripheral arterial
CC thrombosis.
XX
XX Sequence 527 AA;
SQ

Query Match 32.8%; Score 463.5; DB 16; Length 527;
Best Local Similarity 38.9%; Pred. No. 1.8e-33;
Matches 107; Conservative 41; Mismatches 88; Indels 39; Gaps 10;
QY 1 CGLRLLRRQRRIIGKNSLRGWPQVSLRLKSSHDG-RLLCGATLLSCWVLTAAHC 59
DB 264 cglrsgqpqfrkgglfadiashpwwqaafakhrspgrflcggilisscwilsaahc 323
QY 60 F-KRYGNSTRSYAVRVGYHTLVPEEFEEETGVQOIVIHREYRDPDSYDIALVRLQPE 118
DB 324 fgerf--pphlvtlgrtyrvpgeeqkfeykivnkeifddtdyndallqlksds 381
QY 119 EOCARFSSHLVPAQLPL-----WRERPKTASNCYITGWD---TGRAYSRTLQQAII 168
DB 382 sraacessvrvvtclppadlqlpdwte-----celsgyggkhealspfyserlkeav 433
QY 169 PLLPRRFEERY--KGRITGRMLCAG-----NLHEKRVDSQCQDSGGLMCPERP 217
DB 434 alypsrrctsgllnhtvtdmlcagdttrsppqanll-----dacqdsppglvcindg 488
QY 218 ESWVVYGVTSWYCGYGVKDSPGVYTKVSFAVPWIK 252
DB 489 rmtlv-gliiswglgcgkdvpgvvtkvtynidwir 522

RESULT 11
AAR70903
ID AAR70903 standard; Protein; 527 AA.
XX
AC AAR70903;
XX

DT 05-OCT-1995 (first entry)
XX Human t-PA variant (N103,A432,A434).
DE
XX Human wild type tissue plasminogen activator; fibrinolytic; variant;
KW tripeptide; glycosylation site; half-life; clearance rate; blood;
KW clot-dissolving agent; vascular disease; thrombosis; artery; vein.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Domain 1..44 /label= finger domain
FT Domain 45..91 /label= growth factor domain
FT Domain 92..173 /label= kringle 1 domain
FT Domain 180..261 /label= kringle 2 domain
FT Domain 264..527 /label= serine protease domain
FT Disulfide-bond 6..36
FT Disulfide-bond 34..43
FT Disulfide-bond 51..62
FT Disulfide-bond 56..73
FT Disulfide-bond 75..84
FT Disulfide-bond 92..173
FT Disulfide-bond 113..155
FT Disulfide-bond 144..168
FT Disulfide-bond 180..261
FT Disulfide-bond 201..243
FT Disulfide-bond 232..256
FT Disulfide-bond 264..395
FT Disulfide-bond 307..323
FT Disulfide-bond 315..384
FT Disulfide-bond 409..484
FT Disulfide-bond 441..457
FT Disulfide-bond 474..502
FT Modified-site 117 /label= N-linked glycosylation site
FT Modified-site 184 /label= N-linked glycosylation site
FT Modified-site 448 /label= N-linked glycosylation site
FT Modified-site 488 /label= N-linked glycosylation site
XX US5385732-A.
XX 31-JAN-1995.
XX 20-MAY-1988; 88US-0196909.
XX 20-MAY-1988; 88US-0196909.
PR 15-FEB-1990; 90US-0480691.
PR 21-JAN-1992; 92US-0824740.
PR 22-MAR-1993; 93US-0035427.
XX (GETH) GENENTECH INC.
XX Anderson S, Brady KM, Keyt BA, Presta LG;
XX WPI; 1995-081536/11.
XX New tissue plasminogen activator variants - having an N-linked
PT tripeptidyl glycosylation sequence inserted to increase plasma
PT half-life
XX
XX Claim 12; ; 34pp; English.
XX
XX The amino acid sequence of the human tissue plasminogen activator
CC (t-PA) variant N103,A432,A434.
CC This sequence varies from the wild type sequence (AAR70842) by
CC substitutions of AA at pos.: 103 - G to N; 432 - H to A; 434 - R to A.
CC The numbers correspond to the residue positions in the wild type t-PA.
CC

XX 29-AUG-1989; 89WO-0909997.
 XX 24-JUL-1989; 89US-0384608.
 XX 02-SEP-1988; 88US-0240856.
 XX (GETH) GENENTECH INC.
 XX Anderson S, Bennett WE, Botstein D, Higgins DL, Paoni NF;
 XX Zoller M;
 XX WPI; 1990-115987/15.
 XX Modified tissue plasminogen activator - activated only when
 XX proximate to plasmin at site of clot and not systemically
 XX Claim 17; Page 43; 63pp; English.
 XX The t-PA variants represented in AAR09215-63 (and the T252R or N184S
 XX analogues thereof or combinations thereof) and AAR09266-83 have their
 XX fibrinolytic activity turned off when generally in the plasma and
 XX activated when proximate to plasmin at the site of the clot thus
 XX providing specific localised clot therapy.
 XX Sequence 525 AA;

Query Match 32.7%; Score 462.5; DB 11; Length 525;
 Best Local Similarity 39.1%; Pred. No. 2.4e-33;
 Matches 107; Conservative 42; Mismatches 86; Indels 39; Gaps 10;

QY 1 CGLRLHRRKRIIGKNSLRGWPQVSLRLKSSHGDRLLCGATLLSSCWVLTAAHCF 60
 DB 264 cglrysqpfrikglfadiashpwaafakhrspge-rflcgillisscwilsaahcf 322
 QY 61 -KRYGNSTRSYAVRVGDYHTLVPEFEIEIGVQOVIHREYRPSRSDYDIALVRLQGP 119
 DB 323 qerf--pphlhtvlgtrtyrvvpgeekfvekyivhkefdddyndiallqlksdss 380
 QY 120 QCARFSSHVLPACLP-----WRERPKTASNCYITGWD---TGRAYSRTLQQAIP 169
 DB 381 rcaqessvrtclpdpadlqlpdwce-----celsgyghkhealspfyserlkeahv 432
 QY 170 LLPKRFCEERY--KGRFTGRMLCAG-----NLHEHKRVDSQCGSGGGLMCRPGE 218
 DB 433 lypssrctsqhllnrtvtdnmlcagdtgrsggqanlh-----dacqgdsqgplvclndgr 487
 QY 219 SWVYGVTSWGYCGVKDSPGYVTKVSAFVPWIK 252
 DB 488 mtlv-gilswgigcgcgkdvpgvgtkvtynldwir 520

RESULT 14
 AAR092582
 ID AAR092582 standard; protein; 562 AA.
 XX
 XX AAR092582;
 XX
 XX 03-NOV-1990 (first entry)
 XX
 XX Tissue plasminogen activator with S-119 substd for M and QGI96-98
 XX substd for NGT.
 XX
 XX Modified tissue plasminogen activator; tPA; thrombosis; N-glycosylation.
 XX JP63230083-A.
 XX
 XX 26-SEP-1988.
 XX
 XX 20-MAR-1987; 87JP-0264339.
 XX
 XX 20-MAR-1987; 87JP-0264339.
 XX

PA (EISA) EISA KK.
 XX
 XX WPI; 1988-311961/44.
 XX N-PSDB; N825179.
 XX Modified tissue plasminogen activator - having glycine-183 and serine-186
 XX residues sustd. with serine and threonine.
 XX
 XX Disclosure; : 16pp; Japanese.
 XX
 XX One N-glycosylation site, i.e. NSS (117-119) is substituted with
 XX NSM and the N-glycosylation is removed. Site 96-98 OGI is changed to
 XX NGT. Plasmid encoding the modified tPA is 99-6400 and its transformant
 XX is E.coli RRI-Zem 99-6400 (FERM P-9128).
 XX This modified tPA, used to treat thrombosis, is of high quality and
 XX has a longer half life period in blood.
 XX See also AAN82177-N82179.
 XX
 XX Sequence 562 AA;

Query Match 32.7%; Score 462.5; DB 9; Length 562;
 Best Local Similarity 38.9%; Pred. No. 2.4e-33;
 Matches 107; Conservative 41; Mismatches 88; Indels 39; Gaps 10;

QY 1 CGLRLHRRKRIIGKNSLRGWPQVSLRLKSSHGDRLLCGATLLSSCWVLTAAHCF 59
 DB 299 cglrysqpfrikglfadiashpwaafakhrspge-rflcgillisscwilsaahc 358
 QY 60 F-KRYGNSTRSYAVRVGDYHTLVPEFEIEIGVQOVIHREYRPSRSDYDIALVRLQGP 118
 DB 359 fgerf--pphlhtvlgtrtyrvvpgeekfvekyivhkefdddyndiallqlksds 416
 QY 119 EQCARFSSHVLPACLP-----WRERPKTASNCYITGWD---TGRAYSRTLQQAIP 168
 DB 417 srcaqessvrtclpdpadlqlpdwre-----celsgyghkhealspfyserlkeahv 468
 QY 169 LLPKRFCEERY--KGRFTGRMLCAG-----NLHEHKRVDSQCGSGGGLMCRPGE 217
 DB 469 rlypsrctsqhllnrtvtdnmlcagdtgrsggqanlh-----dacqgdsqgplvclndg 523
 QY 218 ESWYGVTSWGYCGVKDSPGYVTKVSAFVPWIK 252
 DB 524 rmtlv-gilswgigcgcgkdvpgvgtkvtynldwir 557

RESULT 15
 AAR46917
 ID AAR46917 standard; Peptide; 356 AA.
 XX
 XX AAR46917;
 XX
 XX 02-JUL-1998 (first entry)
 XX
 XX Amino acid sequence of a novel human kallikrein.
 XX
 XX Kallikrein; HKLP; human; serine protease; drug screening; antagonist;
 XX agonist; treatment; hypertension; cardiac hypertrophy; arthritis;
 XX inflammatory disorder; blood clotting disorder.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 XX Misc-difference 106 /note= "encoded by CRC"
 XX Misc-difference 168 /note= "encoded by YGG"
 XX
 XX WO9803665-A1.
 XX
 XX 29-JAN-1998.
 XX
 XX 21-JUL-1997; 97WO-US12724.
 XX

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 17, 2001, 16:52:11 ; Search time 37.5 Seconds
(without alignments)
1414.560 Million cell updates/sec

Title: US-09-403-724-2
Perfect score: 4905
Sequence: 1 MTLARFVLALMLGALPEVVG.....PGVYTKVSFAFPWIKSVTKL 875

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 412676 seqs, 60623988 residues

Total number of hits satisfying chosen parameters: 412676

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_0601.*
1: /SID88/gcgcdata/geneseq/geneseq/AA1980.DAT.*
2: /SID88/gcgcdata/geneseq/geneseq/AA1981.DAT.*
3: /SID88/gcgcdata/geneseq/geneseq/AA1982.DAT.*
4: /SID88/gcgcdata/geneseq/geneseq/AA1983.DAT.*
5: /SID88/gcgcdata/geneseq/geneseq/AA1984.DAT.*
6: /SID88/gcgcdata/geneseq/geneseq/AA1985.DAT.*
7: /SID88/gcgcdata/geneseq/geneseq/AA1986.DAT.*
8: /SID88/gcgcdata/geneseq/geneseq/AA1987.DAT.*
9: /SID88/gcgcdata/geneseq/geneseq/AA1988.DAT.*
10: /SID88/gcgcdata/geneseq/geneseq/AA1989.DAT.*
11: /SID88/gcgcdata/geneseq/geneseq/AA1990.DAT.*
12: /SID88/gcgcdata/geneseq/geneseq/AA1991.DAT.*
13: /SID88/gcgcdata/geneseq/geneseq/AA1992.DAT.*
14: /SID88/gcgcdata/geneseq/geneseq/AA1993.DAT.*
15: /SID88/gcgcdata/geneseq/geneseq/AA1994.DAT.*
16: /SID88/gcgcdata/geneseq/geneseq/AA1995.DAT.*
17: /SID88/gcgcdata/geneseq/geneseq/AA1996.DAT.*
18: /SID88/gcgcdata/geneseq/geneseq/AA1997.DAT.*
19: /SID88/gcgcdata/geneseq/geneseq/AA1998.DAT.*
20: /SID88/gcgcdata/geneseq/geneseq/AA1999.DAT.*
21: /SID88/gcgcdata/geneseq/geneseq/AA2000.DAT.*
22: /SID88/gcgcdata/geneseq/geneseq/AA2001.DAT.*

12	645	13.1	347	19	AAW64537	Human liver cell c
13	643	13.1	347	19	AAW68200	Human scavenger re
14	643	13.1	347	20	AAV13369	Amino acid sequenc
15	643	13.1	347	22	AAB80237	Human PRO229 prote
16	635	12.9	573	21	AAB49534	Clone HOEC84 #1.
17	598	12.2	774	21	AAB00077	Human lysyl oxidas
18	596	12.2	753	21	AAB00073	Human lysyl oxidas
19	591	12.0	641	21	AAB12307	Human secreted pro
20	591	12.0	754	21	AAB00078	Murine lysyl oxida
21	574	11.7	666	19	AAW64590	Human SRCR protein
22	564.5	11.5	1087	9	AAW80691	Hybrid plasminogen
23	559	11.4	1039	9	AAW80692	Hybrid plasminogen
24	558	11.4	807	13	AAW20013	PA mutant Plg 1-54
25	545	11.1	1113	21	AAV44427	Mouse Serine prote
26	538.5	11.0	704	10	AAW90176	Tissue plasminogen
27	528.5	10.8	1042	21	AAW44426	Human serine prote
28	525.5	10.7	791	18	AAW34285	Human plasminogen
29	523.5	10.7	812	12	AAW12948	Plasminogen mutein
30	522.5	10.7	794	10	AAW90179	Tissue plasminogen
31	521.5	10.6	812	12	AAW12934	Plasminogen mutein
32	520.5	10.6	790	15	AAW60519	Human 'glu' plasm
33	520.5	10.6	810	14	AAW34428	Sequence encoded b
34	519.5	10.6	810	18	AAW31169	Plasminogen protei
35	518.5	10.6	810	12	AAW12938	Plasminogen mutein
36	518	10.6	811	12	AAW12933	Plasminogen mutein
37	518	10.6	811	12	AAW12939	Plasminogen mutein
38	518	10.6	811	12	AAW12943	Plasminogen mutein
39	518	10.6	811	12	AAW12944	Plasminogen mutein
40	517.5	10.6	791	21	AAW01887	Human plasminogen
41	517.5	10.6	791	21	AAW99589	Human plasminogen
42	517.5	10.6	791	21	AAW50867	Human plasminogen
43	517.5	10.6	810	11	AAW08065	Human plasminogen
44	517.5	10.6	810	20	AAW08685	Human plasminogen
45	517.5	10.6	810	20	AAW02114	SEQ ID 77 of W0991

ALIGNMENTS

RESULT 1

AAW83361

AAW83361 standard; Protein; 875 AA.

ID	AAW83361	
XX	AAW83361;	
XX	17-FEB-1999 (first entry)	
DT		Human neurotropsin.
DE		Human neurotropsin.
XX		Human; neurotropsin; tumour inhibition; neurological disease;
KW		lung disease; gene therapy; drug development; stroke; brain injury;
KW		neurodegeneration; neuroinflammatory disease; multiple sclerosis;
KW		epilepsy; hypoxia; ischaemia; nerve transection; neovascularogenesis;
KW		emphysema; bronchitis.
OS		Homo sapiens.
XX		
PN	WO9849322-A1.	
XX		
PD	05-NOV-1998.	
XX		
PF	24-APR-1998; 98WO-IB00625.	
XX		
PR	26-APR-1997; 97CH-0000966.	
XX		
PA	(SOND/) SONDEREGGER P.	
XX		
PI	Sonderegger P;	
XX		
XX		
DR	WPI; 1999-009438/01.	
XX	N-ESDB; AAW72589.	
PT	New human and murine neurotropsin - used, e.g. for inhibiting	

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	DB	ID	Description
1	4905	100.0	875	20	AAW83361	Human neurotropsin
2	4617	94.1	822	20	AAW99087	Human serine prote
3	3481	71.0	761	20	AAW95088	Mouse serine prote
4	3481	71.0	761	20	AAW83362	Mouse neurotropsin
5	983.5	20.1	1785	19	AAW64591	Human SRCR protein
6	830	16.9	1436	22	AAW66088	Bovine WCI protein
7	822.5	16.8	1413	22	AAW66039	Human TANGO 234 ma
8	822.5	16.8	1453	22	AAW66037	Human TANGO 234
9	820.5	16.7	1319	22	AAW66040	Human TANGO 234 ex
10	690.5	14.1	1290	21	AAW07609	Rat von Ebner's gl
11	645.5	13.2	757	18	AAW19127	Polypeptide isolat

```

|||||
Db 121 ggknefeqvegyasvgtvcshwddasvichqlqggkgaiaqtptfsglglpiy 180
Qy 234 WSNVRCRDEENILLCEKDIWQGGVCQKMAAAVTCFSHGTPPIIRLAGGSSVHEGRV 293
Db 181 wsnvrcrgdeenillcekdilwggvcqpkmaaaavtcfsfshgtpfpiiraggssvhegrv 240
Qy 294 ELYHAGOWGTVCDDQDDADAEVICRGLSGIAKAWHOAYFCGEGSPVMDDEVCTGNE 353
Db 241 elyhgagwgtvcddqddadavicrlqglsgiakawhqaayfgegspvmddevctgne 300
Qy 354 LSIQCKSPKSGEHNCGHKEKEDAGVSCPTLTDGVIIRLAGGSGHEGRLEVVYRGOWGTVC 413
Db 301 lsiqcpksswgehnchgedagvscptltdgviraggkshesgrlevyrygwgwtvcd 360
Qy 414 DGWTELNTYVVCRLGFKYKQASANHFESTGPIWLDVSCSGKETRFLOCSRRQGRH 473
Db 361 dgwteintyvcrlgfkgykqasanhfestsipwldvscsgketrflocsrrqgrh 420
Qy 474 DCSHREDVSIACYPGEGHRLSLGFPVRLMDGENKKEGRVEVFINGWGTICDDGWTDKD 533
Db 421 dcshtredvsiacypggeghrslsgfpvrlmdgenkkegrvevfingwgticddgwtkd 480
Qy 534 AAVICRQLGYKGPARTMAYFGEKGGPIHVDNVKCTGNERSLADCTIKDIGHNCRHSE 593
Db 481 aavicrqlgykgparrtmayfgeggkpihvdnvkctgnersladcikdighnchrse 540
Qy 594 DAGVICDYFGKASGNSKESLSSVCGRLRLHRRQKRIIGCKNSLRGGWPQVSLRLKSS 653
Db 541 dagvicdyfgkcasgnskeslssvcgrrllhrrqkrlilggknsllrggwpqvslrlkss 600
Qy 654 HGDGRLLCGATLLSSCWLTAAHCFKRYGNSTRSYAVRVGDYHTLVPEFEETIGVQOIV 713
Db 601 hgdgrllcgatllsscwltaaahcfkrygnstrsyavrvgyhtlvpeefeetigvqviv 660
Qy 714 IHREYRPDRSDYDIALVRLQGPGEQCARFSSHVLPACIPLWRERPKQTASNCYITGWD 773
Db 661 ihreyrpdrrsdydialvrlqgpeeqcarfssshvlpaciplwrerpqktasncyitgwdt 720
Qy 774 GRAYSRTLQQAAILPLPRFCEERYKGRFTGRMLCAGNLHEHKKRVDSGCGSGPLMCE 833
Db 721 grayrtllqqaailplprfceerykgrftgrmlcagnlhehkrvdsccgsgsgplmcer 780
Qy 834 PGESWVYGVTSWVGCGVKDSPGYTKVSFAFVPIKSVTKL 875
Db 781 pgeswvvygvtswvgcgvkdspsytkvsafvpiksvtkl 822

```

RESULT 3

```

AAW99088
ID AAW99088 standard; Protein; 761 AA.
XX
AC AAW99088;
XX
XX 13-MAY-1999 (first entry)
XX
DE Mouse serine protease BSSP-3.
XX
KW Serine protease; BSSP-3; brain tissue.
XX
OS Mus sp.
XX
PN W09905290-A1.
XX
PD 04-FEB-1999.
XX
PF 24-JUL-1998; 98WO-JP03324.
XX
PR 24-JUL-1997; 97JP-0213969.
XX
PA (SUNR ) SUNTORY LTD.
XX
PI Tsuruoka N, Yamaguchi N, Yamashiro K;

```

```

XX WPI; 1999-142942/12.
DR N-PSDB; AAX19027.
XX
PT New serine protease expressed in brain tissue - used in screening
  for potential serine protease inhibitors for drug use
XX
PS Example 1; Page 51-54; 69pp; Japanese.
XX
XX The present sequence is a serine protease designated BSSP-3, which
  is isolated from mouse brain tissue. Transforms may be used to
  produce the enzyme or its partial sequences. Products from the present
  invention are used for screening for potential peptide or non-peptide
  serine protease inhibitors or expression regulators for use as drugs.
XX
SQ Sequence 761 AA;

```

Query Match 71.0%; Score 3481; DB 20; Length 761;
 Best Local Similarity 71.8%; Pred. No. 9.9e-242;
 Matches 628; Conservative 47; Mismatches 86; Indels 114; Gaps 4;

```

Qy 1 MTLARFVLAUMLGALPEVVGFDVSLNDSLHSHRHPAGPHYYPYLTQQRPPPTRRPP 60
Db 1 mtlarcvlavilgalsvvaradpysrplhrph-pspprsqh-ahylpsrrprt---- 54
Qy 61 PLPRFPRPALPAQRPHALQAGHTPRPHWGPCPAGEPWSVTDGACPLRWAEVPPFLE 120
Db 55 --prfpplr-ipaqrprqvistghtptiprcgagsgnatnlgvpclhwdvppfle 112
Qy 121 RSPASWALRGQRHFCRSPDAGRPWCYGDARKVDWGYDCDRHGSVRLRGKNEFE 180
Db 113 rspaswaelrgqhncfcrspdgsgprpcwfyrnaqkvdwgycdc----- 157
Qy 181 GTVEVYASVGMGTVCSSHWDSDASVICHQLGLGGIAKQTPFSGILGPIIYWSNVRCR 240
Db 158 ----- 157
Qy 241 GDEINILLCEKDIWQGGVCQKMAAAVTCFSHGTPPIIRLAGGSSVHEGRVELYHAGQ 300
Db 158 -----gggpalpavrlvgngshgrevlyhagq 186
Qy 301 WGTVCDDQDDADAEVICRGLSGIAKAWHOAYFCGEGSPVMDDEVCTGNEISLEQCP 360
Db 187 wgticddqddadavicrlqglsgiakawhqaayfgegspvmddevctgncleseqcp 246
Qy 361 KSSWGEHNCGHKEKEDAGVSCPTLTDGVIIRLAGGSGHEGRLEVVYRGOWGTVCDDGWT 420
Db 247 ksswgehnchgedagvscptltdgviraggkshesgrlevyrygwgwtvcdgwteln 306
Qy 421 TYVVCRLGFKYKQASANHFESTGPIWLDVSCSGKETRFLOCSRRQGRHDCSHRED 480
Db 307 tyvacrilgfkgykqasanhfestsipwldvscsgketrflocsrrqgrhdcshred 366
Qy 481 VSIACYPGEGHRLSLGFPVRLMDGENKKEGRVEVFINGWGTICDDGWTDKDAVTCRQ 540
Db 367 vgticpdsdghrlslspgfpvrlmdgenkkegrvevfingwgticddgwtkdhaavtc 426
Qy 541 LGYKGPARTMAYFGEKGGPIHVDNVKCTGNERSLADCTIKDIGHNCRHSEDAVYCD 600
Db 427 lgykgparrtmayfgeggkpihmdnvkctgnekaladcvcqkdigrhncrshsedavycd 486
Qy 601 YFGKKASGNSKESLSSVCGRLRLHRRQKRIIGCKNSLRGGWPQVSLRLKSSHGDGRLL 660
Db 487 ylekkasgnsnkemlssvcgrrllhrrqkrlilggknsllrggwpqvslrlshgdgrll 546
Qy 661 CGATLLSSCWLTAAHCFKRYGNSTRSYAVRVGDYHTLVPEFEETIGVQOIVIHREYRP 720
Db 547 cgatllsscwltaaahcfkrygnstrsyavrvgyhtlvpeefeetigvqvivihryrp 606
Qy 721 DRSDYDIALVRLQGPGEQCARFSSHVLPACIPLWRERPKQTASNCYITGWDGTGRAYSRT 780
Db 607 drsdydialvrlqgpeeqcarlshvlpaciplwrerpqktasncytgwdtgraysrt 666

```

KW autoantibody; ss.

OS Homo sapiens.

PN WO9830687-A2.

XX 16-JUL-1998.

XX 09-JAN-1998; 98WO-DE00096.

XX 18-JUL-1997; 97DE-1030997.

XX 09-JAN-1997; 97DE-1000519.

XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX Mollenhauer J, Poustka A;

XX WPL; 1998-399136/34.

XX N-PSDB; AAV49652.

XX Proteins containing scavenger receptor, cysteine rich domain -

XX useful for diagnosis and treatment of tumours

XX Claim 2; Fig 2; 54pp; German.

XX This sequence represents a human protein which contains a SRCR (scavenger
CC receptor, cysteine-rich) domain. The gene and encoded protein can be used
CC to diagnose or treat tumours, particularly of the nervous system
CC (medullo-blastoma or glioma) or breast. The DNA sequence and probes
CC derived from it, are used to identify genes that express SRCR-domain
CC containing proteins, to determine the form in which these proteins exist
CC and to assess the significance of individual forms on cellular
CC properties. The protein can be used to detect the presence of
CC autoantibodies and antibodies which regulate its expression.

XX Sequence 1785 AA;

Query Match 20.1%; Score 983.5; DB 19; Length 1785;
Best Local Similarity 28.8%; Pred. No. 4.7e-62;
Matches 294; Conservative 92; Mismatches 353; Indels 283; Gaps 38;

QY 20 GFDSVL-----NDSLHSHRHSPAGPHYLYLPTQORPTTRPPPLPRFRPPRALPA 74
DB 434 gyesylwscphngwlsnchqhsdag-----vicsaahswstpsdtlptitpastvgs 488
QY 75 Q-----RPHALQAGHTRPRHPMGPAGEPWSVTFDGPCLR-----WAE 114
DB 489 eesslallrlvnggdrccgrvevlygg-----swgtvcddsw-dtndanvvcrgpgcgwam 541
QY 115 VPP-----FLERSPPASWALRGQRHNCFRSPDGAGRPW-----CFYGDARGKV- 158
DB 542 sapgnarfsggsgplvldvrcsdhe-----sywscphngwlsnchghsedagvic 593
QY 159 -----DMGYCDCHRGSS-----VRLRGKNEFECTVEVYASGVWGTVCSS 197
DB 594 sasqsrtpspdtw---ptshastagesslallrlvnggdrccgrvevlyrgswgtvcdd 650
QY 198 HMDSDASVICHQLQGLGKGIAKOTFFS---GLGLIPIYWSNVRGDEENILLCEKDIW 254
DB 651 ywtdndanvvcrl---gcgwamsapgnarfsggsgplvldvrcsdhesylwscphngw 707
QY 255 QGVCVQKMAAAVTCFSHGTFP-----IIRLAGGSSVHEGRVEL 295
DB 708 lshncghhedagvicsasqsgtpspdtwptshastagesslallrlvnggdrccgrvev 767
QY 296 YHAGOMGTCDOWDDDAEVICRQLGLSGLIAKAWHQAYFGEGSPVMDREVTGNELS 355
DB 768 lyrgswgtvcdddywtdndanvvcrlgswatsapgnarfsggsgplvldvrcsdhesy 827
QY 356 IEQCPKSSWGEHNCGHKEDAGVSC-----TPLTDG-----VIRLAGGK 393
DB 828 lwschphngwlsnchghhedagvicsasqsgtpspdtwptshastagesslallrlvngg 887

QY 394 GSHEGRLEVVYRGOMGTVCDDGDTLNTYVVCROLGFKYKQASAN-HFEESTGPIWLDD 452
DB 888 drcrgrvevlyrgswgtvcdddywtdndanvvcrlgswatsapgnarfsggsgplvldd 947
QY 453 VSCSGKTRFLQCSRWRHDCSHREDVSIACYPGGF-----GHR 493
DB 948 vrcsghesylwscphngwlsnchghhedagvicsaasqsgtpdpdtwlttnlpaltvgse 1007
QY 494 LSLGFPVRLMDGENKKEGRVEVFINCQMGTCICDDGWTDKDAVTCRQLGYGKPARARTMA 553
DB 1008 ssla--irlvnggdrccgrvevlyrgswgtvcddswtdndanvvcrlgswatsapgn 1065
QY 554 YFGEKGPIHVDNKTGNERSLADCIKQDIGHNCRHSEDAGVIC-----DYFG 603
DB 1066 rfggsgplvldvrcsdhesylwscphkgwlnchghhedagvicsatqinsttdwh 1125
QY 604 KKASGNSNKESLSSVCGLLRHRRQKRIIG-----KNSLRGWPQV----- 646
DB 1126 pttttarp---ssncggflfy-----asgtfsspsypaypnnakcvweievnsyri 1176
QY 647 -----SLRLKSSHG-----DGRLLCGATLLSSCWVLTAAHCFKRYGNSSTRSYAVRV 692
DB 1177 nlgsfnlkiahncsfdyveifdgslnsllgkic-----ndtrq--lft 1221
QY 693 GDYHTLVPEFEIEIGVQOIVIHREYRDRSDYDIALVRLQGPESQCARFSSHVLPAQLP 752
DB 1222 ssymrt-ihfrdisfngtflawynsfpsdatirlvlnssyglca----- 1268
QY 753 LWRERPKTASNCYITG-WGDTGRVSRVLTQOAAIPLLPKRCFEERYKGRFTGRMLCAGN 811
DB 1269 -----grveiyhggtwg-tvcddswtqaeav-----vcrqlgcgravsai---gn 1310
QY 812 LHEHKRVDSQCQDGGGPL-----MCERPGESWVYGVTSWVGCGVKDSP 856
DB 1311 ay-----fgsgsgpittldvccsgtestlwqcnrg--w-----fshncnhreda 1353
QY 857 GV 858
DB 1354 gv 1355
RESULT 6
AAB66088
ID AAB66088 standard; Protein; 1436 AA.
XX
AC AAB66088;
XX
DT 30-MAR-2001 (first entry)
XX
DE Bovine WC1 protein.
XX
KW Gene therapy; TANGO protein; INTERCEPT protein; neurological disorder;
KW central nervous system; focal brain disorder; bipolar affective disorder;
KW global-diffuse cerebral disorder; cerebrovascular; Alzheimer's disease;
KW senile dementia; Huntington's disease; amyotrophic lateral sclerosis;
KW Parkinson's; Gilles de la Tourette's syndrome; hypertension; sleep;
KW neuropsychiatric; psychoactive substance use; anxiety.
XX Bos sp.
XX WO200077239-A2.
XX
XX 21-DEC-2000.
XX
XX 24-MAY-2000; 2000WO-US14858.
XX
XX 14-JUN-1999; 99US-0333159.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX McCarthy SA, Fraser CC, Sharp JD, Barnes TM;
XX

central nervous system (CNS) disorders, CNS-related disorders, focal brain disorders, global-diffuse cerebral disorders and other neurological and cerebrovascular disorders. The CNS disorders include Alzheimer's disease, senile dementia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's, Gilles de la Tourette's syndrome, autonomic function disorders such as hypertension and sleep disorders, neuropsychiatric disorders, psychoactive substance use disorders, anxiety, and bipolar affective disorder.

Query Match 16.8%; Score 822.5; DB 22; Length 1453;
Best Local Similarity 34.7%; Pred. NO. 1.3e-50;
Matches 189; Conservative 73; Mismatches 188; Indels 95; Gaps 12;

QY 166 RHGSVRLRGKKEFEFTVEYASGVMTVCSSSHWDDSDASVICHOLQ-----LGGKGI 218
DB 896 RYTDVRLVNGKSGQDQVVEINVLGWSICDTHWDEARVLCRLSGTALSTGGKYI 955
QY 219 AKQTPFSLGLIPIYMSNVRCRDEENILLCEKDIWQGVCPQKMAAAVTCFSF-HGPTTF 277
DB 956 GERS-----VRVWGHrfhclgnesalldncqmtvlgapcrlhngntsvictgslqplf 1008
QY 278 PI-----IRLAGSSVHEGRVELYHAGOWGTVCDDQWDDA 312
DB 1009 pclanvsdpylsavpegsalclcdkrlrlvldgdsrcaqrvelyhdgfwgtdcdgwdls 1068
QY 313 DAEVICRQLGLGIAKAWHQAVFEGSGVPMLDEVRCTNELSIEQCPKSSWGEHNCGHK 372
DB 1069 dahvvcqkigcgvafnatvsahtgsgpwiiddlnctgteshlwqcpargwqghdcrhk 1128
QY 373 EDAGVSCVTPLTDGVRIRLAGKGSHE--GRLEVYRQWGTVCDDGWTENLYVVRQLGF 430
DB 1129 edagvicseft--alrlysetetescagrlevfyngtwsgvgrnittaagivcrqlgc 1186
QY 431 -KYGKQASANHFESTGPIWLDVSCSGKETRFLOCSRRQWRHDCSHREDVSIACYPGG 489
DB 1187 gengvslaplsktsqgmvmvddlqcpkthislwqclsapwerriisspaetwited-- 1244
QY 490 EGHRLSLGFPVRLMDGKNKKEGRVEVFINGQWGTICDDGWTDKDAAVICRQLGKYPARA 549
DB 1245 -----rivrvgdtecsgrvelwhagswtgvtcdsdwlaeaeavvcqlgcgsalaa 1295
QY 550 RTMAYFEGGKGPVHVDNVKCTGNERSLADCIKODIGHNCRHSESDAGVICDYFGKASGN 609
DB 1296 lrdasfgggtgtiwlmdmrckgnesflwdchakpwgsgdcghkedagvrc-----sq 1348
QY 610 SNKE-----SLSSVCGLLRL-----HRRQKRIIGKNSLRGGMWQVSL 648
DB 1349 slkslnassghlalilssifgllllvflftwcrvqkqkhl-----plrvt 1397
QY 649 RLKSS 653
DB 1398 rrrgs 1402

RESULT 9
AAB66040
ID AAB66040 standard; Protein; 1319 AA.
XX
AC AAB66040;
XX
DT 30-MAR-2001 (first entry)
XX
DE Human TANGO 234 extracellular domain.
XX
KW TANGO protein; INTERCEPT protein; neurological disorder;
KW central nervous system; focal brain disorder; bipolar affective disorder;
KW global-diffuse cerebral disorder; cerebrovascular; Alzheimer's disease;
KW senile dementia; Huntington's disease; amyotrophic lateral sclerosis;
KW Parkinson's; Gilles de la Tourette's syndrome; hypertension; sleep;
KW neuropsychiatric; psychoactive substance use; anxiety.

central nervous system; focal brain disorder; bipolar affective disorder;
global-diffuse cerebral disorder; cerebrovascular; Alzheimer's disease;
senile dementia; Huntington's disease; amyotrophic lateral sclerosis;
Parkinson's; Gilles de la Tourette's syndrome; hypertension; sleep;
neuropsychiatric; psychoactive substance use; anxiety.

Homo sapiens.
WO200077239-A2.
21-DEC-2000.
24-MAY-2000; 2000WO-US14858.
14-JUN-1999; 99US-0333159.
(MILL-) MILLENNIUM PHARM INC.
McCarthy SA, Fraser CC, Sharp JD, Barnes TM.
WPI; 2001-032313/04.
DR N-PSDB; AAF45123, AAF45124.
XX
XX TANGO and INTERCEPT nucleic acids, proteins, and antibodies, useful for
XX screening assays and diagnostic assays and for the treatment of
XX neurological diseases such as Alzheimer's, Parkinson's and Huntington's
XX disease -
XX
XX Claim 8; Fig 2; 359pp; English.
XX
XX The present invention relates to TANGO or INTERCEPT proteins and coding
XX sequences (see AAF45121-F45136 and AAF45138-F45139 and AAB66031-B66057,
XX AAB66064-B66083 and AAB66085). The TANGO/INTERCEPT proteins and coding
XX sequences are useful for the treatment of neurological disorders such as

QY 313 DAEVICRQLGLSGIAKAWHQAYFGE GSGPVM LDEV RCTGNELSI EQCPKSSWGEHNCGHK 372

PA XX

PA XX

QY 555 FGEGKPIHVDNVCCTGNERSLADCIKODIGRHNCRHSEDAGVIC 599
 Db 301 YGPGVGRWLDNVRCSGEQSLQCHRFWGFHDCTHGEDVAVIC 345

RESULT 13
 AAW68200
 ID AAW68200 standard; Protein; 347 AA.
 XX AC AAW68200;
 XX DT 07-DEC-1998 (first entry)
 XX DE Human scavenger receptor protein SP alpha.
 XX SP alpha; scavenger receptor; SRCR; human; antibody; immunoassay;
 KW immunomodulator; autoimmune disease; transplant rejection;
 KW infection; tumour; immunodeficiency; therapy.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT Peptide 1..19
 FT /label= Sig_peptide
 FT Protein 20..347
 FT /label= Mat_protein
 FT Domain 24..125
 FT /note= "cysteine-rich domain"
 FT Domain 138..239
 FT /note= "cysteine-rich domain"
 FT Domain 245..346
 FT /note= "cysteine-rich domain"
 XX W09839443-A1.
 XX 11-SEP-1998.
 XX 05-MAR-1998; 98WO-US04370.
 XX 06-MAR-1997; 97US-0039956.
 XX (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX Aruffo AA, Gebe JA, Siadak AW;
 XX WPI; 1998-495847/42.
 XX N-PSDB; AAV54605.
 XX New scavenger receptor cysteine-rich protein - the antibodies of
 XX which can be used to modulate the immune response
 XX Claim 7; Fig 1A-B; 46pp; English.
 XX This is the amino acid sequence of a novel protein (see AAW68200),
 CC termed SP alpha, that is a member of the scavenger receptor
 CC cysteine-rich (SRCR) family. The sequence was deduced from an
 CC isolated cDNA clone (see AAV54605). SP alpha transcripts are found
 CC in human bone marrow, spleen, lymph node, thymus and foetal liver
 CC but not in non-lymphoid tissues. SP alpha has the same domain
 CC organisation as the extracellular region of CD5 and CD6 and is
 CC composed of 3 SRCR domains. It is capable of binding to cells of
 CC the monocytic lineage, and appears to be involved in the regulation
 CC of monocyte activation, function and/or survival, and is therefore
 CC an important component in the immunoregulatory system. Methods of
 CC recombinantly producing SP alpha are disclosed. In addition,
 CC antibodies reactive with SP alpha are provided, as are methods of
 CC using antibodies that bind to SP alpha for modulating the
 CC interaction between SP alpha and its receptor. SP alpha can be used
 CC in pharmaceutical compositions to regulate the immune response in,
 CC for example, autoimmune disease, viral infections, transplant
 CC rejection suppression, tumour cell proliferation suppression, and
 CC combined variable immunodeficiency.

XX SQ Sequence 347 AA;
 Query Match 13.1%; Score 643; DB 19; Length 347;
 Best Local Similarity 40.0%; Pred. No. 1.8e-38;
 Matches 138; Conservative 45; Mismatches 114; Indels 48; Gaps 10;
 QY 280 IRLAGSSVHEGRVELYHAGQWGTVCDDQWDADAEVICTRQLGLSGIAKAMHQAVFGSGS 339
 Db 24 vrlvgllhrcegrveqkgwgtvcddgdwdikdvaviclelqcg-----aasgtps 75
 QY 340 G-----PVMLDEVRCCTGNELSTEQCPKSSWGSHNCGHKEDAGVSC-----TP 381
 Db 76 gilyeppaekedkvlsqsvstcgtedtiaqceqee--vydeshdedagascenpessfsp 133
 QY 382 LTDGVTIRLAGSGSHEGRLEVYIRGQWGTVCDDGWTELTNTYVVCROLGFKYQK-----QAS 437
 Db 134 vpegv-rladgphckgrvevkhqpwytvcqtgswlraakvvc:qlg--cgravltqkr 190
 QY 438 ANHFESTGPIWLDVSCSGKTRFLQCSRRQRWRHDCSHREDVSIACYPGEGHRLSIG 497
 Db 191 cnkhaygrkpiwlsqmscsgreatlqdcpsgpwgkntcnhdetwveced-----p 241
 QY 498 FVRLMDGENKKEGRVEVFINGQWGTICDDGWTDKDAVICRQLGYKGPAPA---RTMAY 554
 Db 242 fdrlvggdnllcsgrlievlhkgvsgvcdnwgkedqvckqlgc-gkslpsfdrkc 300
 QY 555 FGEGKPIHVDNVCCTGNERSLADCIKODIGRHNCRHSEDAGVIC 599
 Db 301 YGPGVGRWLDNVRCSGEQSLQCHRFWGFHDCTHGEDVAVIC 345

RESULT 14
 AAY13369
 ID AAY13369 standard; Protein; 347 AA.
 XX AC AAY13369;
 XX DT 25-JUN-1999 (first entry)
 XX DE Amino acid sequence of protein PRO229.
 XX Secreted protein; transmembrane protein; human; enterocolitis;
 KW Zollinger-Ellison syndrome; gastrointestinal ulceration;
 KW congenital microvillus atrophy; skin disease; cell growth;
 KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
 KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy;
 KW fibromodulin; dermal scarring; Usher Syndrome; Atrophla areata;
 KW anti-thrombotic; wound healing; tissue repair.
 XX OS Homo sapiens.
 XX WO9914328-A2.
 XX 25-MAR-1999.
 XX 16-SEP-1998; 98WO-US19330.
 XX 25-NOV-1997; 97US-0066840.
 XX 17-SEP-1997; 97US-0059113.
 XX 17-SEP-1997; 97US-0059115.
 XX 17-SEP-1997; 97US-0059117.
 XX 17-SEP-1997; 97US-0059119.
 XX 17-SEP-1997; 97US-0059121.
 XX 17-SEP-1997; 97US-0059122.
 XX 17-SEP-1997; 97US-0059184.
 XX 18-SEP-1997; 97US-0059263.
 XX 18-SEP-1997; 97US-0059266.
 XX 15-OCT-1997; 97US-0062125.
 XX 17-OCT-1997; 97US-0062285.
 XX 17-OCT-1997; 97US-0062287.
 XX 21-OCT-1997; 97US-0063486.

Search completed: July 17, 2001, 16:55:27
Job time: 196 sec